Amoebiasis is an infection caused by the single-celled parasite Entamoeba histolytica, and it kills an estimated 55,000 people every year, mostly in tropical and subtropical regions with poor sanitation.1Open Forum Infectious Diseases. A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis The infection ranges from completely silent to life-threatening, and that wide spectrum is part of what makes it so tricky to manage. Prevalence in some populations reaches as high as 40%, yet the vast majority of those people never develop symptoms.
How You Catch It
The parasite spreads through a dormant form called a cyst, which is shed in the stool of an infected person. Cysts are tough. They resist temperature swings, pH changes, and the acidic environment of the stomach, allowing them to survive on contaminated hands, food, and water for extended periods.2PLoS Pathogens. Entamoeba Encystation: New Targets to Prevent the Transmission of Amebiasis Once swallowed, a cyst passes through the stomach and hatches in the small intestine, releasing the active feeding form of the parasite, called a trophozoite. These trophozoites migrate to the large intestine, where they multiply and colonize the gut lining. Some eventually transform back into cysts and get excreted, completing the cycle. Trophozoites that leave the body in stool die quickly in the environment, so only the cysts are infectious.3PLoS Pathogens. Entamoeba Encystation: New Targets to Prevent the Transmission of Amebiasis
Contaminated water is a major transmission route. In one study of humans and non-human primates sharing water sources in Tanzania, researchers found E. histolytica in all three groups studied, consistent with waterborne transmission.4PubMed Central. Entamoeba histolytica infection in humans, chimpanzees and baboons in the Greater Gombe Ecosystem, Tanzania In endemic regions, any fecally contaminated surface, from raw produce to household utensils, can carry cysts. Travelers returning from endemic areas and men who have sex with men are additional recognized risk groups in higher-income countries.
What the Parasite Does Inside You
Most of the time, E. histolytica lives in the large intestine without causing any harm. The trophozoites graze on bacteria and debris, multiply, and cycle back to cysts that get shed in stool. In a minority of infected people, however, the trophozoites turn invasive. They attach to the intestinal lining using a surface molecule called Gal/GalNAc lectin, which binds to sugars on human cells. Once attached, the parasite deploys several weapons: enzymes that dissolve tissue and pore-forming molecules that puncture cell membranes.
One of the more striking discoveries about E. histolytica is its method of killing. Researchers found that the parasite literally takes bites of living human cells, a process they named trogocytosis (from the Greek word for “nibble”). The amoeba ingests distinct pieces of a living cell, causing calcium to flood in and the cell to die. After the cell is dead, the amoeba detaches and moves on.5PubMed Central. Trogocytosis by Entamoeba histolytica contributes to cell killing and tissue invasion This nibbling is not just a quirky behavior. By ingesting fragments of human cells, the amoeba decorates its own surface with human membrane proteins, essentially wearing a disguise that helps it evade the immune system and survive in human serum.6PubMed Central. Trogocytosis by Entamoeba histolytica Mediates Acquisition and Display of Human Cell Membrane Proteins and Evasion of Lysis by Human Serum
When invasion reaches the intestinal wall, the tissue destruction creates characteristic flask-shaped ulcers: narrow at the surface and wider beneath, like an upside-down bottle. These ulcers are a hallmark of amoebic colitis and can be confirmed on biopsy.7Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy. Chronic Hematochezia Caused by Amoebic Colitis with Multiple Flask-Shaped Colonic Ulcers: A Case Report
Symptoms of Intestinal Amoebiasis
When the infection does cause illness, the most common presentation is amoebic colitis. Symptoms typically develop gradually over one to three weeks and include cramping abdominal pain, loose or bloody stools, and an urgent need to use the bathroom. Unlike bacterial dysentery, which tends to hit hard and fast with fever and watery diarrhea, amoebic colitis often creeps in with intermittent bloody mucus in the stool and lower abdominal tenderness. Fever is less common than you might expect. In severe cases, the colon wall can become so damaged that it perforates, a surgical emergency. A rare but dangerous complication called toxic megacolon, where the colon dilates and becomes paralyzed, can also occur.
Chronic amoebic colitis sometimes mimics inflammatory bowel disease, leading to misdiagnosis. This is a real clinical trap, because the standard treatment for inflammatory bowel disease (immunosuppressive drugs) can make amoebiasis dramatically worse. Clinicians working in or treating patients from endemic areas need to keep amoebiasis on the list of possibilities before starting immunosuppressive therapy.
Amoebic Liver Abscess and Other Complications
If trophozoites breach the intestinal wall and enter the bloodstream, they can seed other organs. The liver is the most common target because blood from the intestines drains into it via the portal vein. Amoebic liver abscess is the most frequent extraintestinal complication and tends to appear in the right lobe of the liver.8PubMed Central. Amebic liver abscess: An update Patients typically present with right upper abdominal pain, fever, and a tender, enlarged liver. Many of them do not recall having had diarrhea, which can delay the diagnosis.
Less commonly, the parasite reaches the lungs, brain, or skin. Disseminated amoebiasis is rare but has been documented even outside endemic settings. One case report described a patient who developed intestinal amoebiasis with spread to the liver, peritoneum, lungs, brain, and skin, in a non-endemic country where the source of infection was never identified.9PubMed Central. An Unexpected Case of Disseminated Amebiasis with Cerebral Involvement and Successful Recovery in a Non-Endemic Context These unusual cases serve as a reminder that amoebiasis can show up anywhere in the body, not just the gut.
The Male Predominance Puzzle
One of the more curious patterns in amoebiasis is the lopsided sex ratio for liver abscesses. Men develop amoebic liver abscess roughly 10 times more often than women, and most cases occur between the ages of 20 and 40.10Open Forum Infectious Diseases. A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis Intestinal infection rates, by contrast, are roughly equal between sexes. The reasons remain poorly understood, but animal studies have confirmed the disparity is biological, not just behavioral. In mouse models, males consistently developed more severe liver abscesses than females, suggesting hormones or sex-linked immune differences play a role.11PubMed Central. Sexual dimorphism in the control of amebic liver abscess in a mouse model of disease Alcohol consumption, which is higher on average in men and has been associated with amoebic liver abscess, may be another contributing factor.12PubMed Central. Amebic liver abscess: An update
Why Diagnosis Is Harder Than It Looks
For decades, amoebiasis was diagnosed by looking at stool under a microscope and spotting cysts or trophozoites. The problem is that E. histolytica, the species that actually causes disease, is visually identical to Entamoeba dispar, a harmless species that lives in the gut without ever invading tissue. A third lookalike, E. moshkovskii, adds further confusion. In a study of stool samples from patients in Sydney, PCR testing revealed that E. dispar was present in about 71% and E. moshkovskii in about 62% of the positive samples, while true E. histolytica was found in only five patients.13PubMed Central. PCR detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii in stool samples from Sydney, Australia In other words, most of what a microscope calls “amoeba” in a stool sample turns out to be a harmless species.
This matters because overdiagnosing E. histolytica leads to unnecessary treatment with metronidazole, a drug that carries its own side effects and contributes to resistance pressure. One Brazilian study found that among 27 stool samples positive for the E. histolytica/E. dispar complex by microscopy, only two actually contained E. histolytica when tested by molecular methods. The rest were E. dispar.14Brazilian Journal of Infectious Diseases. Comparison of multiplex-PCR and antigen detection for differential diagnosis of Entamoeba histolytica
Antigen-detection kits offer a step up from the microscope but have their own limitations. In non-endemic settings, some commercial ELISA kits showed sensitivities as low as 28% when compared against PCR, and one widely used kit failed to detect any confirmed E. histolytica-positive samples, making it essentially useless in that context.15PubMed Central. Comparison of stool antigen detection kits to PCR for diagnosis of amebiasis PCR-based tests are the most reliable, with one comparative study reporting 100% sensitivity and over 98% specificity against microscopy as a reference.16PubMed Central. A Comparative Analysis of Microscopy, Coproantigen Serology, and Nested Multiplex PCR in the Laboratory Diagnosis of Entamoeba histolytica Infection The challenge is that PCR is not available everywhere, especially in the low-resource settings where amoebiasis is most common.
Treatment Requires Two Steps, Not One
A common misunderstanding is that a single course of antibiotics clears amoebiasis. In reality, treatment for symptomatic disease requires two separate drugs targeting different stages of the parasite. The first is a tissue-active drug, almost always metronidazole or a related nitroimidazole, which kills the invasive trophozoites in the intestinal wall, liver, or other organs. Metronidazole works by being activated inside the parasite, where an enzyme called thioredoxin reductase converts it into a toxic form that damages proteins the amoeba needs to survive.17PubMed Central. Nitroimidazole Action in Entamoeba histolytica: A Central Role for Thioredoxin Reductase
Metronidazole alone does not reliably kill the cysts sitting in the intestinal lumen. If you stop there, the remaining cysts can re-establish the infection or be passed to others. A second “luminal” drug such as paromomycin is needed to mop up any cysts left behind.18Open Forum Infectious Diseases. A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis In a Japanese study, all 11 patients with cyst-positive stools became negative after paromomycin treatment, confirming its effectiveness for luminal clearance.19PubMed. Efficacy and safety of paromomycin for treating amebiasis in Japan People with asymptomatic infections (carriers who are shedding cysts but have no symptoms) only need the luminal agent, since there is no tissue invasion to treat.20Open Forum Infectious Diseases. A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis
Why Your Gut Bacteria May Decide Whether You Get Sick
One of the more active areas of amoebiasis research involves the gut microbiome. Clinical evidence suggests that the bacteria living in your intestines influence whether E. histolytica infection stays silent or turns dangerous.21PubMed Central. The Intestinal Bacterial Microbiome and E. histolytica Infection In a study of children in Bangladesh, those who developed diarrhea from E. histolytica had a distinct gut microbiome compared to uninfected children, with lower levels of a bacterium in the genus Lachnoclostridium. When researchers introduced a related species, Clostridium scindens, into the guts of mice, it protected them from the parasite, and this protection was tied to stronger neutrophil recruitment to the site of infection.22JCI Insight. Gut microbiome communication with bone marrow regulates susceptibility to amebiasis
The mechanism connecting gut bacteria to immune defense has been fleshed out further. In mice with disrupted gut flora (dysbiosis), neutrophils showed reduced surface expression of CXCR2, a receptor that normally helps them migrate toward an infection. These mice had fewer neutrophils arriving at the intestinal wall during E. histolytica invasion, leading to more severe tissue damage. The oxidative killing power of those neutrophils was also weaker.23PubMed Central. Learning from the research on amebiasis and gut microbiome The broader implication is that anything that disrupts your gut bacteria, whether antibiotic use, poor diet, or other illness, could lower your defenses against amoebiasis.
The Immune Response and Why Most People Clear It
Neutrophils are among the first immune cells to confront invading amoebae. When activated, they release reactive oxygen species that can kill trophozoites directly. Depleting neutrophils in mouse models led to worse intestinal disease, confirming their protective role.24PLoS Pathogens. Host Immune Response to Intestinal Amebiasis On the adaptive side, mucosal IgA antibodies targeting the parasite’s lectin have been linked to protection in children. In a cohort of preschool children in Dhaka, Bangladesh, those who produced IgA against the carbohydrate recognition domain of the lectin were less likely to become infected or develop disease.25PLoS Pathogens. Host Immune Response to Intestinal Amebiasis
This finding has practical significance: it suggests that a vaccine stimulating mucosal IgA against the Gal/GalNAc lectin could replicate the natural protection seen in these children. The fact that the immune system can and does fight off E. histolytica in most people helps explain why only a fraction of infected individuals ever get sick. But it also highlights how much depends on immune competence: malnourished children, immunosuppressed patients, and people with disrupted gut flora are all at elevated risk of progression.
Drug Resistance on the Horizon
Metronidazole has been the backbone of amoebiasis treatment for decades, and outright clinical resistance remains uncommon. But laboratory studies paint a more cautious picture. When researchers selected E. histolytica for metronidazole resistance in the lab, the resistant amoebae showed increased levels of iron-containing superoxide dismutase (Fe-SOD) and peroxiredoxin, both antioxidant enzymes that neutralize the toxic compounds metronidazole generates. At the same time, expression of ferredoxin 1, which is involved in activating the drug, went down. Overexpressing Fe-SOD alone reduced the parasite’s susceptibility to metronidazole, and combining Fe-SOD with peroxiredoxin amplified the effect further.26PubMed. Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase This means the parasite has a clear biochemical path to resistance, even if it has not yet taken that path widely in clinical settings. Given how heavily we rely on nitroimidazoles and how few alternatives exist, this is a vulnerability in the treatment toolkit.
Vaccine Development
No vaccine against amoebiasis exists for human use, but research has been underway for years. The leading candidate targets the Gal/GalNAc lectin, the same surface molecule the parasite uses to attach to human cells. Vaccinations using native and recombinant forms of this lectin have successfully protected animals against both intestinal amoebiasis and liver abscess.27PubMed Central. The future for vaccine development against Entamoeba histolytica Other antigens, including the serine-rich protein and a 29-kDa reductase antigen, have shown promise against liver abscess specifically.28PubMed Central. The future for vaccine development against Entamoeba histolytica
More recently, researchers have been fine-tuning vaccine delivery. A recombinant form of the lectin antigen (called LecA) was paired with a liposomal adjuvant containing synthetic immune-stimulating molecules targeting two different immune receptors. In mice, different adjuvant combinations steered the immune response in different directions: one boosted the mucosal IgA that is known to be protective against intestinal infection, while another promoted a stronger cell-mediated immune response. Combining both adjuvants elicited both types of protection simultaneously.29npj Vaccines. Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica The Gal-lectin-based vaccines remain the most advanced, but human clinical trials have not yet been conducted.
The Lookalike Problem and What It Means for Global Burden Estimates
The inability of standard microscopy to distinguish E. histolytica from its harmless relatives has distorted our understanding of how common amoebiasis actually is. For much of the 20th century, every microscopic identification of the E. histolytica/E. dispar complex was counted as a case of potential amoebiasis. It was not until the 1980s that researchers confirmed E. dispar was a separate, non-pathogenic species, despite being morphologically identical. This distinction took nearly a century to resolve after the parasite was first linked to dysentery and liver abscess in the late 1800s.
The practical upshot is that many older prevalence figures are inflated, lumping harmless E. dispar carriers in with genuinely infected individuals. Even today, in laboratories that rely solely on microscopy, the same conflation continues. This is not an academic footnote. It means people get treated for amoebiasis they do not have, while the true burden of E. histolytica in populations that lack molecular testing remains uncertain. The global estimate of more than 55,000 deaths per year is itself imprecise, reflecting the difficulty of counting a disease whose diagnosis depends on tools many affected regions cannot access.
Prevention Without a Vaccine
In the absence of a vaccine, prevention relies on breaking the fecal-oral transmission cycle. Clean water, functional sewage systems, and good hand hygiene are the most effective measures, which is why amoebiasis disproportionately affects regions where these are lacking. For travelers, the standard advice applies: drink bottled or boiled water, avoid raw produce you did not peel yourself, and be cautious about ice and street food in endemic areas. Cysts are resistant to standard chlorination at the concentrations used in many municipal water systems, so even treated water can be a risk in areas with heavy contamination.
Identifying and treating asymptomatic carriers is another control strategy. Because carriers continually shed cysts in their stool, they serve as a silent reservoir, passing the infection to others even though they feel fine. Treating carriers with a luminal agent like paromomycin eliminates cyst shedding and cuts the chain of transmission. This approach is most practical in household contacts of confirmed cases or in institutional settings such as group homes, where person-to-person spread is more likely. Since blocking cyst formation would halt transmission entirely, researchers have explored this as a pharmaceutical strategy, though no drug specifically targeting encystation is yet available for clinical use.30PLoS Pathogens. Entamoeba Encystation: New Targets to Prevent the Transmission of Amebiasis